Masonic Cancer Center, University of Minnesota: Leukemia trials
The registry lists 60 Leukemia studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 0 are open to participants now and 33 have results posted.
Phase 1 20Phase 2 39Phase 3 2No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
- Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
- A Study of FMT in Patients With AML Allo HSCT in RecipientsCompletedNCT03678493Phase 2Results posted
- Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted
- QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AMLCompletedNCT03050216Phase 2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML PatientsCompletedNCT02395822Phase 2Results posted
- HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or LymphomaCompletedNCT02370160Phase 1/2Results posted
- Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesTerminatedNCT02145039Not applicableResults posted
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
- Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
- T-Cell Depleted Double UCB for Refractory AMLTerminatedNCT01464359Phase 2Results posted
- Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01312818Phase 2Results posted
- Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)TerminatedNCT01106950Phase 2Results posted
- Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00882206Phase 2Results posted
- Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AMLTerminatedNCT00871689Phase 2Results posted
- Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaTerminatedNCT00818649Phase 2Results posted
- Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00630565Phase 2/3Results posted
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00625729Phase 1/2Results posted
- Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 2Results posted
- Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell TransplantationTerminatedNCT00609739Phase 1/2Results posted
- Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other DiseaseTerminatedNCT00392782Phase 2Results posted
- Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaCompletedNCT00357565Phase 2Results posted
- Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.TerminatedNCT00354172Phase 2Results posted
- Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
- Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2Results posted
- Study of Immune Response Modifier in the Treatment of Hematologic MalignanciesTerminatedNCT00276159Phase 2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00274846Phase 2Results posted
- Stem Cell Transplant for Hematological MalignancyTerminatedNCT00176930Not applicableResults posted
- Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT00167219Phase 1/2Results posted
- Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
- Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALLWithdrawnNCT05114837Phase 1/2
- Study of Periodontitis and Blood Stream Infection in AML Patients Receiving ChemotherapyTerminatedNCT04858594
- Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive ChemotherapyCompletedNCT03728699
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient InductionCompletedNCT03316456
- Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLCompletedNCT03081780Phase 1
- StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme MalignanciesWithdrawnNCT02765997Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaWithdrawnNCT01677949Phase 2
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete RemissionWithdrawnNCT01639456Phase 2
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or LymphomaCompletedNCT00889408Phase 1
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic LeukemiaTerminatedNCT00643240Phase 1
- Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced LeukemiaTerminatedNCT00618696Phase 1
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable
- Bone Marrow Transplantation in Treating Patients With LeukemiaWithdrawnNCT00006451Phase 3
- Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous LeukemiaTerminatedNCT00005986Phase 2
- Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous LeukemiaTerminatedNCT00005984Phase 2